cPDM in AeroSpace and Defence Market Leading 11 Key-Players Revenue, Shares, Sales and Forecasts Till 2026 | COVID19 Impact Analysis | Key Players:…

cPDM in AeroSpace and DefenceMarket research report provides various levels of analysis such as industry analysis (industry trends), market share analysis of top players, and company profiles, which together provide an overall view on the competitive landscape; emerging and high-growth segments of the cPDM in AeroSpace and Defencemarket; high-growth regions; and market drivers, restraints, challenges, and opportunities.

The cPDM in AeroSpace and Defencemarket report elaborates insights on the Market Diversification (Exhaustive information about new products, untapped regions, and recent developments), Competitive Assessment (In-depth assessment of market shares, strategies, products, and manufacturing capabilities of leading players in the cPDM in AeroSpace and Defencemarket).

Premium Insights on cPDM in AeroSpace and Defence Market 2020 with Market Players PositioningRequest For Exclusive Sample PDF Copy:https://inforgrowth.com/sample-request/6335853/cpdm-in-aerospace-and-defence-market

Market segmentation based on the Key Players, Types & Applications.

cPDM in AeroSpace and DefenceMarket on the basis of Product Type:Software, Service,

cPDM in AeroSpace and DefenceMarket on the basis of Applications:Military, Civilian,

Top Key Players in cPDM in AeroSpace and Defencemarket: SAP AG, CIMdata, IBM Corp, Oracle Corp, HP, Dassault Systemes SA, Siemens PLM Software Inc, Autodesk Inc, Parametric Technology Corp, Synopsys Inc, Capgemini, Deloitte, Accenture Plc,

This report brings together multiple data sources to provide a comprehensive overview of cPDM in AeroSpace and Defence.

It includes analysis on the following

Make Inquiry for More Insights:https://inforgrowth.com/enquiry/6335853/cpdm-in-aerospace-and-defence-market

Reasons to Buy cPDM in AeroSpace and Defencemarket Report:

Get Special Discount for this Premium Report:https://inforgrowth.com/discount/6335853/cpdm-in-aerospace-and-defence-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898

Read more from the original source:

cPDM in AeroSpace and Defence Market Leading 11 Key-Players Revenue, Shares, Sales and Forecasts Till 2026 | COVID19 Impact Analysis | Key Players:...

COVID-19 Update: Global Civil Aerospace Simulation and Training Market is Expected to Grow at a Healthy CAGR with Top players: CAE, FlightSafety…

Civil Aerospace Simulation and Training MarketResearch Report covers the present scenario and the growth prospects of Civil Aerospace Simulation and Trainingd Market for 2015-2026. The report covers the market landscape and its growth prospects over the coming years and discussion of the Leading Companies effective in this market. Civil Aerospace Simulation and Training Market has been prepared based on an in-depth market analysis with inputs from industry experts. To calculate the market size, the report considers the revenue generated from the sales of Civil Aerospace Simulation and Training globally

This report will help youtake informed decisions, understand opportunities, plan effective business strategies, plan new projects, analyse drivers and restraints and give you a vision on the industry forecast.Further, Civil Aerospace Simulation and Training market report also covers the marketing strategies followed bytop Civil Aerospace Simulation and Training players, distributors analysis, Civil Aerospace Simulation and Training marketing channels, potential buyers and Civil Aerospace Simulation and Training development history.

Get Exclusive Sample Report on Civil Aerospace Simulation and Trainingd Market is available at https://inforgrowth.com/sample-request/6335950/civil-aerospace-simulation-and-training-market

Along with Civil Aerospace Simulation and Training Market research analysis, buyer also gets valuable information about global Civil Aerospace Simulation and Training Production and its market share,Revenue, Price and Gross Margin, Supply, Consumption, Export, Import volumeand values for followingRegions:

In the Civil Aerospace Simulation and Training Market research report, following points market opportunities, market risk and market overview are enclosed along with in-depth study of each point. Production of the Civil Aerospace Simulation and Training is analyzed with respect to various regions, types and applications.The sales, revenue, and price analysis by types and applicationsof Civil Aerospace Simulation and Training market key players is also covered.

Civil Aerospace Simulation and Training Market Segment considering Production, Revenue (Value), Price Trend byType:Fixed-Wing, Rotary-Wing,

Civil Aerospace Simulation and Training Market Segment by Consumption Growth Rate and Market Share byApplication:Manoeuvre, Defense,

Civil Aerospace Simulation and Training Market Covers following MajorKey Players:CAE, FlightSafety International, L-3 Link Simulation & Training, St. Jude Medical, Rockwell Collins, Thales, Airbus, ECA, FRASCA International, Lockheed Martin, SIMCOM Aviation Training,

Is there any query or need customization? Ask to our Industry [emailprotected]https://inforgrowth.com/enquiry/6335950/civil-aerospace-simulation-and-training-market

Impact of COVID-19:Civil Aerospace Simulation and TrainingMarket report analyses the impact of Coronavirus (COVID-19) on the Civil Aerospace Simulation and Trainingindustry.Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Civil Aerospace Simulation and Trainingmarket in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Download the Sample ToC and understand the COVID19 impact and be smart in redefining business strategies.https://inforgrowth.com/CovidImpact-Request/6335950/civil-aerospace-simulation-and-training-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898

Follow this link:

COVID-19 Update: Global Civil Aerospace Simulation and Training Market is Expected to Grow at a Healthy CAGR with Top players: CAE, FlightSafety...

cPDM in AeroSpace and Defence to Witness Growth Acceleration During 2019-2025 – Owned

The global cPDM in AeroSpace and Defence Marketplace gives detailed Evaluation about all of the important aspects related to the marketplace. The analysis on global cPDM in AeroSpace and Defence market, offers profound insights about the cPDM in AeroSpace and Defence market covering all of the crucial characteristics of the market. Moreover, the report provides historical information with prospective prediction over the forecast period. Various important aspects like market trends, revenue development patterns market shares and supply and demand are included in almost all the market research report for every single business. Some of the vital aspects analyzed in the report includes market share, production, key regions, revenue rate as well as key players.

The study of different sections of the global market are also Covered in the research report. Along with that, for the prediction periods conclusion of variables such as market size and the competitive landscape of this sector is assessed in the report. On account of the rising globalization and digitization, there are new tendencies coming to the marketplace daily. The research report provides the in-depth analysis of all of these tendencies.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2724377&source=atm

In addition, the cPDM in AeroSpace and Defence market report also supplies the Latest tendencies in the international cPDM in AeroSpace and Defence market with the assistance of primary as well as secondary research methods. Also, the analysis report on cPDM in AeroSpace and Defence marketplace gives a wide evaluation of the market which includes market review, manufacturing, manufacturers, dimensions, price, value, growth rate, income, deals, export, consumption, and sales revenue of this global cPDM in AeroSpace and Defence market. On the other hand, the cPDM in AeroSpace and Defence market report also studies the industry standing for the prediction period. Nevertheless, this can help to increase the advertising opportunities throughout the world in addition to major market providers.

segment by Type, the product can be split intoSoftwareServiceMarket segment by Application, split intoMilitaryCivilian

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2724377&source=atm

The cPDM in AeroSpace and Defence market report provides helpful insights for Every established and advanced players across the world. Additionally the cPDM in AeroSpace and Defence marketplace report provides accurate analysis for the shifting competitive dynamics. This study report includes a whole analysis of future growth concerning the evaluation of this mentioned prediction interval. The cPDM in AeroSpace and Defence marketplace report provides a thorough study of the technological growth outlook over time to be aware of the industry growth rates. The cPDM in AeroSpace and Defence market report also includes innovative analysis of the massive number of unique factors that are fostering or operating as well as regulating the cPDM in AeroSpace and Defence marketplace development.

A systematized methodology can be used to create a Study on the Global cPDM in AeroSpace and Defence Sector. For the analysis of market on the terms of research Approaches, these strategies are useful. All the Information Regarding the Products, makers, vendors, clients and even more is covered in research reports. Various important factors like market trends, earnings Growth patterns market stocks and supply and demand are contained in almost all The market research report for every single business. Adaptation of new thoughts and Accepting the latest tendencies are a few the reasons for any markets growth. The Global cPDM in AeroSpace and Defence market research report gives the deep understanding about the Areas in which the marketplace is impactful.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2724377&licType=S&source=atm

See the article here:

cPDM in AeroSpace and Defence to Witness Growth Acceleration During 2019-2025 - Owned

Brodalumab for the Treatment of Psoriasis in Patients With HIV – Dermatology Advisor

Home Topics Psoriasis

Brodalumab may be an effective treatment for refractory psoriasis in patients with human immunodeficiency virus (HIV), suggests case study data published in Dermatologic Therapy.

Investigators described the case of a 62-year-old man with HIV who presented with worsening and persistent plaque psoriasis. His Psoriasis Area and Severity Index (PASI) score was 20.0, indicating moderate to severe disease. Erythema and scaling were observed in large areas on the scalp, trunk, and extremities. The patient was taking highly active antiretroviral therapy (HAART) for HIV and had serological evidence of past co-infection with hepatitis B and C. Thepatient had tried ultraviolet B phototherapy and cyclosporine for psoriasis. Cyclosporine was discontinued due to loss of efficacy and replaced with ustekinumab, which also became ineffective after 1 year.

The patient was started on brodalumab at the recommended dosage of 210 mg every 2 weeks. Marked improvement in plaque psoriasis was observed; a PASI score of 0 was achieved after 6 weeks of treatment. Sustained remission was observed at 6 months. Control of HIV was maintained, with no opportunistic infections or laboratory abnormalities over follow-up.

Data from this case suggest that brodalumab may be an option for patients with HIV who have exhausted other psoriasis therapies. However, administration of an IL-17 inhibitor to a patient with HIV must be done with caution, due to the role of IL-17 in preventing candidiasis. Patients with HIV are highly susceptible to Candida infection, although HAART decreases this susceptibility. The current patient did not experience candidiasis. [A]dditional experience is required before IL-17 inhibitors can be regarded as a standard therapy in moderate to severe HIV-associated psoriasis, investigators wrote.

Reference

Di Lernia V, Casanova DM, Ricci C. Brodalumab: another helpful option for HIV-positive psoriatic patients? [published online June 25, 2020]. Dermatol Ther. doi: 10.1111/dth.13895

Please login or register first to view this content.

LoginRegister

Read the original here:

Brodalumab for the Treatment of Psoriasis in Patients With HIV - Dermatology Advisor

European Commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima SC, for an additional five…

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that the European Commission (EC) has granted marketing authorisation for Remsima (infliximab, CT-P13) subcutaneous (SC) formulation for the treatment of adult patients with ankylosing spondylitis, Crohns disease, ulcerative colitis, psoriatic arthritis and psoriasis.1

The approval follows a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in June and is based on data from a pivotal study comparing the pharmacokinetics, efficacy and safety of the SC and intravenous (IV) formulations of Remsima in people with active Crohns disease and ulcerative colitis, throughout a 1-year treatment period.2,3 Based on the results of the pivotal study, a 120 mg fixed dose of Remsima SC has been approved for use in the European Union (EU), in adults regardless of body weight, in both existing and newly added indications.

Professor Stefan Schreiber, Director of the Clinic for Internal Medicine at Kiel Campus of the University Hospital Schleswig-Holstein in Germany said: The subcutaneous formulation of Remsima (Remsima SC) has been shown to have very high efficacy, and favourable data, which are fully comparable to the efficacy and safety profile of the IV formulation. Todays approval marks an important progress for the gastroenterology community as it means that treatment can now be administered in significantly less time, thereby providing patients more flexibility and control over how they receive their treatment.

We are pleased to announce this important regulatory milestone earlier than we expected, with the European Commission prioritising review of this important new administration option. We will accelerate the launch process on a country-by-country basis in order to expand treatment options for patients with chronic inflammatory diseases such as inflammatory bowel disease and ankylosing spondylitis, said Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare. We will do our best to make Remsima SC available as early as possible and hope this medication will contribute to minimising the risks involved with administering medical treatments during the COVID-19 pandemic.

Celltrion anticipates receiving approval of Remsima SC in 97 countries, including 31 countries in Europe.

-- ENDS --

Notes to Editors:

About Remsima (CT-P13) intravenous (IV) formulation1Remsima IV is usually given as 3 mg per kg/body weight in rheumatoid arthritis (RA) and as 5 mg per kg/body weight for the other indications. Infliximab IV is given as an infusion over two hours. All patients are monitored for any reactions during the infusion and for at least one to two hours afterwards.

About Remsima CT-P13 subcutaneous (SC) formulation4,5A 120 mg fixed dose of Remsima SC has been granted marketing authorisation in the EU, in adults regardless of body weight, in all previously approved indications for the IV formulation. Remsima SC has three administration options; via a pre-filled pen (auto injector), pre-filled syringe or pre-filled syringe with needle safeguard. The SC formulation has the potential to enhance treatment options for the use of infliximab biosimilar by providing high consistency in drug exposure and a convenient method of administration.

About CT-P13 (biosimilar infliximab)CT-P13 is developed and manufactured by Celltrion, Inc. and was the worlds first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including RA and IBD. It was approved by the EC under the trade name Remsima in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra. CT-P13 is approved in more than 94 countries (as of July 2020) including the US, Canada, Japan and throughout Europe.

About Celltrion HealthcareCelltrion Healthcare is committed to delivering innovative and affordable medications to promote patients access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us

Forward-looking statement disclaimerCertain information set forth in this press release contains statements related to our future business and financial performance, and future events or developments involving Celltrion Healthcare, that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as will, has potential to, brings, if approved, would, could, opportunity, hope, is considering the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand managements beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or managements estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References

1 European Medicines Agency Summary of Product Characteristics (SmPC). Remsima.

2 Reinisch W, et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase 1 open-label randomised controlled trial in patients with active Crohns disease. European Crohns and Colitis Organisation 2019. Abstract no: A-1103.

3 Ben-Horin S, et al. A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohns disease and ulcerative colitis. Oral presentation (OP24). Presented at ECCO 2020.

4 Yoo DH, Jaworski J, Matyska-Piekarska E et al. A Novel Formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: One-year results from part one of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis. Poster (FRI0128). Presented at EULAR 2019.

5 Westhovens R, Wiland P, Zawadzki M et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 30-week results from part two of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis. Poster (SAT0170). Presented at EULAR 2019.

More here:

European Commission grants marketing authorisation for world's first subcutaneous formulation of infliximab, Remsima SC, for an additional five...

MC2 Therapeutics Announces US Food and Drug Administration Approval of Wynzora Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)…

COPENHAGEN, Denmark, July 22, 2020 / B3C newswire / -- MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older.

The FDA approval is based on the results of the US Phase 3 clinical trial (1) against active comparator Taclonex Topical Suspension (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%). A total of 794 patients were randomized in this trial and the primary efficacy endpoint was the proportion of patients with PGA treatment success at week 8 defined as at least a 2-grade improvement from baseline in PGA to clear or almost clear. The difference in PGA treatment success to the active comparator was 14.6% (95% CI; 7.6%, 21.6%) in favor of Wynzora Cream.

Reduction of itch as defined by at least a 4-point improvement in the 11-point peak pruritus numeric rating scale (NRS) from baseline to week 4 was assessed among patients who had at least a peak pruritus NRS score of 4 at baseline. A higher proportion of patients achieved at least a 4-point improvement in the peak pruritus NRS score at week 4 in the Wynzora Cream group (60.3%) compared to vehicle (21.4%).

Wynzora Cream is a novel topical treatment for plaque psoriasis which offers a unique combination of high efficacy, favorable safety and excellent treatment convenience in a single product, said Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, Michigan, and lead principal investigator in the study.

Studies show that more than half of psoriasis patients are dissatisfied with their treatment and that a large proportion of patients are not treated at all (2).

The FDA approval marks an important milestone for patients with plaque psoriasis", stated Jesper J. Lange, CEO of MC2 Therapeutics and continued: "Our PAD Technology has uniquely enabled us to develop Wynzora Cream with no compromises. It drives the compelling efficacy and safety data of Wynzora Cream and transforms that data into impact for patients through a convenient formulation that allows patients to move on within minutes of a morning routine. It puts patients back in control of therapy and daily life."

Founder and Executive Chairman of MC2 Therapeutics, Mads Clausen concurred: "Wynzora is a prime example of what we envision PAD Technology can do to help patients, physicians and payers release the full potential of topical therapies in real world settings."

With the US approval, the recent submission of its marketing authorization application of Wynzora Cream in EU, and its ongoing interactions with payers, physicians and patient organizations MC2 Therapeutics is well on track to launch Wynzora Cream in major territories. In addition, MC2 Therapeutics continues development of its pipeline of new topical therapies within major chronic inflammatory indications such as atopic dermatitis, uremic pruritus, lichen sclerosus and dry eye.

About Plaque PsoriasisPsoriasis is a common, non-contagious, chronic skin disease, with no clear cause or cure. The negative impact of plaque psoriasis on peoples lives can be immense as it affects the appearance of the skin with red, scaly plaques. According to the National Psoriasis Foundation, itch is present in between 70 and 90 percent ofpsoriasispatients, and together with flaking and scaling, itching is the most burdensome symptom to patients (3,4,5). The appearance of flares of psoriasis can be unpredictable and affects people of all ages. With a reported prevalence of 2-4% of the population psoriasis constitutes a serious health problem with more than 100 million individuals affected worldwide. More than 90% of patients receiving treatment use topical drugs. Patients with psoriatic disease are at an elevated risk of developing other chronic and serious health conditions, including arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease and depression (5).

About Wynzora Cream Wynzora Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. Wynzora Cream is based on PAD Technology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in a convenient-to-use aqueous formulation. In the phase 3 trials conducted at multiple sites in the US and the EU, Wynzora Cream has demonstrated a unique combination of compelling clinical efficacy, a favorable safety profile and high convenience. These features of Wynzora Cream hold promise to lead to less treatment discontinuation and overall better patient satisfaction in topical treatment of plaque psoriasis in the real-world setting.

Indication and UsageWynzora (calcipotriene and betamethasone dipropionate) Cream is a prescription medicine indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.

Apply WynzoraCream to affected areas once daily for up to 8 weeks and not more than 100 grams per week. Patients should stop treatment when the plaque psoriasis is under control unless a healthcare provider gives other instructions.

Wynzora Cream is for use on skin only (topical). Do not get Wynzora Cream near or in your mouth, eyes, or vagina. Avoid using Wynzora Cream on your face, groin, or armpits, or if you have thinning of your skin (atrophy) at the treatment site.

It is not known if Wynzora Cream is safe and effective in children.

Important Safety InformationTell your healthcare provider about all your medical conditions and all the medicines you take, including any corticosteroid medicines and any other products containing calcipotriene.

Do not use other products containing calcipotriene or a corticosteroid medicine without talking to your healthcare provider first.

Wynzora Cream may cause side effects, including:

The most common side effects include upper respiratory infection, headache, and application site irritation. These are not all the possible side effects. Call your healthcare provider for medical advice about side effects.

This summary is not comprehensive. Visit http://www.wynzora.com to obtain the FDA-approved Full Prescribing Information.

About PAD TechnologyPAD Technology formulations are tailor-made to meet the target product profile for a selected product candidate. PAD Technology enables the mixing of oil and water into a cream using just a fraction of the emulsifier required in conventional creams and lotions. Key features of PAD Technology formulations are high penetration of active ingredients to the target tissue, improved solubility and stability of active ingredients, high tolerability and excellent treatment convenience.

About MC2 TherapeuticsMC2 Therapeutics is a privately held commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions. Using its PAD Technology it aims to set a new standard of treatment experience for patients and to release the full potential of novel topical drugs for the benefit of patients, physicians, payers and societies. PAD Technology is the basis for its innovative pipeline of drug candidates within atopic dermatitis, uremic pruritus, lichen sclerosus, and dry eye.

Contacts

MC2 TherapeuticsInvestors: Lonni Goltermann+45 2018 1111 This email address is being protected from spambots. You need JavaScript enabled to view it.

MediaEU: Molecule A/S: Mette Thorn Sorensen, +45 4138 4300 or This email address is being protected from spambots. You need JavaScript enabled to view it.US: Amy Phillips, +1 412.327.9499 or This email address is being protected from spambots. You need JavaScript enabled to view it.

References:

1. Clinical trial ID: NCT033087992. Armstrong et al. JAMA Dermatol. 2013;149(10):1180-11853. http://www.psoriasis.org/life-with-psoriasis/managing-itch (accessed July 13th, 2020)4. The Voice of the Patient, Psoriasis. FDA Public Meeting Report, 20165. WHO Global report on Psoriasis 2016

Keywords: Humans; betamethasone dipropionate, calcipotriol; calcipotriene; Prostaglandins A; Patient Satisfaction; Drug Users; United States Food and Drug Administration; Betamethasone; Calcitriol; betamethasone-17,21-dipropionate; Taclonex; Psoriasis; Drug Combinations; Treatment Outcome; Marketing

Published by B3C newswire and shared through Newronic

Read this article:

MC2 Therapeutics Announces US Food and Drug Administration Approval of Wynzora Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)...

Psoriasis Drug Being Used To Treat COVID-19; Why Itolizumab? – Inventiva

The year 2020 began with a not-so-great scenario that escalated rapidly into a pandemic that has crippled the functioning of the world. A lot has happened over the course of these past 4 months with a large number of people losing their lives to a microscopic virus. Coronavirus and COVID-19 are words that are familiar to every person in the world since it has made a huge impact on everything that rules peoples hectic lives; Business, economy and simply put, their way of living. The novelty of the virus is a research field in itself with scientists looking into its morphology and genetic structure, discovering new facts about this unknown microorganism. With most of the people who got affected being asymptomatic, scientists also have to work faster to detect the properties of this virus and easier ways to detect it to increase the number of people being tested per day. Therefore, it is a need of the hour for those susceptible to have a vaccine they can rely on that will be effective in helping them develop immunity against this virus. With the rush to develop a vaccine, many countries have applied for their drug compounds to be used for phase 3 or phase 4 trials. COVAX, an initiative by Gavi, a public-private partnership, to support the acceleration of the designing, development, and distribution of vaccines. With countries around the world trying to find a vaccine, about 130 vaccines are under testing in various phases. India is also actively taking part in this vaccine rush and has 2 possible drugs in different trial stages; Covaxin by Bharat Biotech and ZyCov-D by Zydus which are proving to be hopeful. Along with these two, Biocon, a global biopharma company based in Bangalore, recently announced that they have received a green flag from the Drug Controller General of India to release their novel biologic, Itolizumab (ALZUMAb) into the market for restricted emergency use in treating COVID-19 patients with moderate to severe complications.

But why is Itolizumab, a drug used in treating a chronic skin disease like psoriasis, being used to treat patients affected with COVID-19?

The SARS-CoV-2 virus affects individuals by triggering the immune system to generate a large number of cytokines which can attack the organs like lungs, etc. and can lead to multiple organ failure or death. Here is where Itolizumab seems to help the affected individuals.

Kiran Mazumder-Shaw, the Executive Chairperson of Biocon, said in a press release that this novel drug has been approved by the regulator, based on the promising data obtained from a pivotal two-arm, randomized trial involving 30 eligible patients across New Delhi and Mumbai. Out of these 30 patients, 20 were administered with Itolizumab with the best care, making them the test arm and the remaining 10 were not administered Itolizumab, making them the control arm. After a period of one month, the mortality rates were observed. The results were promising, as all 20 of the test arm patients experienced a full recovery. 3 patients out of the 10 in the control arm died.

Itolizumab proved itself to be efficient by meeting the key efficacy parameter of improving lung function without a hike oxygen flow as required by the patients in the control arm and also displayed suppression or reduction in the expression of clinical markers of inflammation. It has also worked tremendously in controlling moderate to severe ARDS (Acute Respiratory Distress Syndrome) induced by COVID-19 and has shown its efficacy in treating elder patients too. This clinical trial proved to be helpful in giving emergency treatment options to patients to reduce complications. Itolizumab, the psoriasis drug turned COVID-19 treatment, is shown to work best if administered before the cytokine release begins and helps to prevent the cytokine storm from intensifying.

This drug can be the best bet since it already is available in the market for the treatment of psoriasis, implying the fact that it is safe for human usage which has been proven by the 4 phase trials that were conducted before its release in 2013 by Biocon. Itolizumab acts by binding to the CD6 receptor and modulating it to prevent the T-lymphocyte activation thereby reducing the cytokine storm that turns into a deadly immune response.

Biocon is very well known for its unique biologics and pharmaceutical products in India and has a lot of global connections, Equillium being one of them. Equillium, a biotechnology company is planning to initiate a global study of this novel drug, Itolizumab, to make sure a large number of people get benefitted within a short period. Equillium is partnering with Biocon for Itolizumab in U.S., Canada, Australia, and New Zealand.

Bruce Steel, the co-founder, and CEO of Equillium said that they are working with Biocon to assess the further processes involved in accelerating the use of Itolizumab to treat COVID-19 patients in the U.S and abroad. The drug is being evaluated at present under two INDs for treating acute graft-vs-host disease and lupus nephritis, plus a clinical study in uncontrolled asthma in Australia and New Zealand.

Similarly, Itolizumab has been used to treat COVID-19 patients in Cuba too. The reports from Cuba were similar to the one obtained in the trial done in India and it shows a very low mortality rate in the patients who were administered with Itolizumab. The dosage being administered is a 25mg/5ml formulation at the rate of 4 vials per patient. Each vial costs Rs. 7,950. Therefore, the total dosage costs around Rs. 35,000.

The success and approval of Itolizumab show us that we can still hope for a better tomorrow with many individuals carrying out endless research works to find a solution. The efforts are enormous and we can only hope for them to be fruitful. With vaccines under trial and testing, the best we, as general citizens, can do is to stay calm and help others do the same. It is our responsibility to take enough care of our health and in this case, the health of our loved ones too.

Like Loading...

Related

Go here to see the original:

Psoriasis Drug Being Used To Treat COVID-19; Why Itolizumab? - Inventiva

Factbox: What progress is Britain making on post-Brexit trade deals? – Reuters UK

LONDON (Reuters) - Britain is negotiating several bilateral trade deals to come into effect once its exit from the European Union is complete at the end of the year.

FILE PHOTO: European Union and British flags flutter in front of a chancellery ahead of a visit of British Prime Minister Theresa May in Berlin, Germany, April 9, 2019. REUTERS/Hannibal Hanschke/File Photo

The Department for International Trade has prioritised deals with the EU, the United States, Japan, Australia and New Zealand. Heres where things stand:

Total trade value: 232.7 billion pounds (1)

Both sides have said they want a quick deal, but there are clear hurdles. The United States elects a new president in November, and the UK says there is no set timetable because it does not want time pressure to be used against it.

Two rounds of talks have taken place so far, with the third expected to begin on Monday. Both sides have described the talks as constructive and positive, but there are underlying tensions.

The United States imposed retaliatory tariffs on EU exports, including some from Britain, after a row over aircraft subsidies. Britain has demanded that those tariffs, which apply to a wide range of goods including Scotch whisky and tailored suits, be removed to show goodwill.

Other high-profile issues include whether a deal will give U.S. firms access to Britains state-funded healthcare system, and whether Britain will accept U.S. food hygiene standards. The British government says the National Health Service is not on the table, and food standards will not be lowered.

Total trade value: 673 billion pounds (1)

Britain and the European Union have held six formal rounds of talks on a trade agreement to form part of a deal on their future relationship when a status quo transition period expires at the end of this year.

Both sides agreed last month to speed up their talks but their positions are far apart, particularly on the level playing field guarantees of fair competition and on fisheries.

Britain said after the last round that an agreement could be reached in September; EU officials say the earliest any breakthrough could come is towards the end of August.

Total trade value: 18.6 billion pounds (1)

Britain said in its negotiating mandate, published on June 17, that it wanted an ambitious and comprehensive deal including a focus on technology, innovation and research and development.

The first round of talks was held remotely between June 29 and July 10. Trade minister Liz Truss said: Discussions between negotiators were productive and reflected our shared ambition to secure a comprehensive deal to boost trade and investment between our like-minded economies.

The next round of talks is planned for September.

Total trade value: 31.6 billion pounds (1)

Negotiations began in June. Both sides have said they want a deal to come into force by the end of 2020.

Tokyo wanted to conclude talks by the end of July, but Truss has since said she will not be bounced into signing a deal because of time pressure.

Britain says any deal with Japan should be at least as good as the one signed with the EU, and that that deal can be used as a template to speed the process up.

British analysis estimated that, in the long run, the trade deal could increase annual trade flows between both countries by 15.2 billion pounds and increase the size of the UK economy by 1.5 billion pounds.

Total trade value: 2.9 billion pounds (1)

Britain said in its negotiating mandate, published on June 17, that it wanted an ambitious and comprehensive deal supporting both governments Net Zero commitments on climate change.

The first round of trade talks began via videoconference on July 13 and concluded on July 24. Further rounds are expected in due course, Britain said.

(1) Office for National Statistics, UK total trade; all countries, non-seasonally adjusted, 2019, as of July 23.

here

Reporting by William James and Elizabeth Piper; Editing by Kevin Liffey

See original here:

Factbox: What progress is Britain making on post-Brexit trade deals? - Reuters UK

Tony Blair calls for an investigation into Russian involvement in Brexit referendum – The New European

Video

PUBLISHED: 11:05 27 July 2020 | UPDATED: 11:50 27 July 2020

Adrian Zorzut

Former prime minister Tony Blair. Photograph: Stefan Rousseau/PA.

PA Wire/PA Images

Email this article to a friend

To send a link to this page you must be logged in.

Become a Supporter

Almost four years after its creation The New European goes from strength to strength across print and online, offering a pro-European perspective on Brexit and reporting on the political response to the coronavirus outbreak, climate change and international politics. But we can only continue to grow with your support.

The former Labour prime minister said the probe was a matter of national security.

Speaking after Boris Johnson dismissed a parliamentary committees recommendation for an investigation, Blair said: Were still with one of the best security services in the world - youve got to build the capability to investigate what foreign governments are trying to do in interfering with our system and expose it and the more you expose it, the less effective it will be or the less it will happen.

I think it would be sensible to investigate what has happened but really, the most important thing is to create the capacity for the future, to make sure that you know whats going on in your democratic politics because this interference - and its only one aspect of cyber-security, by the way - this interference is going to be more and more widespread because the capabilities are much greater.

Blairs comments come after the Intelligence and Security Committee (ISC), a Westminster panel tasked with scrutinising Britains intelligence community, released a 50-page report detailing instances of Moscows interference in UK elections and institutions.

The document, dubbed the Russia report, claimed wealthy Russian figures with connection to president Vladimir Putin regularly donate to British political parties.

It called Russian involvement in British institutions the new normal and blasted successive governments for not wanting to address the issue of the 2016 vote with a 10-foot pole.

According to a survey by pollsters Opinium, almost half of the British public (49%) think that the Kremlin interfered in the 2016 vote, including 39% of those who voted for Leave and 63% who supported Remain.

Head of polling at Opinium, Adam Drummond, said: Although the EU referendum is the most obvious example, whats interesting is the consistent pattern across all election and referendums over the past five years where around half of voters believe that the Russian government interfered with our political process, and this belief is about twice as high among Remain voters as Leave voters.

That said, the fact that more believe it happened than did not happen and that 66% of UK adults put Russia in the threat category, suggests a degree of political consensus about the problem in the future.

Touching on the committees findings, Blair added: We live in a new world today where cyber-security is going to be a massive, massive question for government and there are governments that want to weaken the West; we know basically why they want to do it, and weve just got to make sure that they are all the time constrained.

Blair added that it would be foolish to think the referendum result was a consequence of Russian interference.

Almost four years after its creation The New European goes from strength to strength across print and online, offering a pro-European perspective on Brexit and reporting on the political response to the coronavirus outbreak, climate change and international politics. But we can only rebalance the right wing extremes of much of the UK national press with your support. If you value what we are doing, you can help us by making a contribution to the cost of our journalism.

Follow this link:

Tony Blair calls for an investigation into Russian involvement in Brexit referendum - The New European

Freedom of movement and the importance of being Brexit-ready – SME Magazine

SMEs thrive on attracting and retaining the brightest and best talent, but with forthcoming changes heralding the restriction of movement for EU citizens, they could find themselves unable to employ who they want, when they want to.

Lawyers are advising companies to get ready for the new immigration rules, knowing that failure to do so could have a dramatic effect on future growth and recruitment plans.

Following recent government announcements, it is clear that Brexit is still very much on the cards for the end of the year and companies need to prepare for the new immigration laws coming into force on January 1.

These laws mean that, to employ EU nationals currently not living in the UK after that, all business, no matter what size, will need a Sponsor Licence. This licence grants a company permission from the Home Office to employ overseas staff previously something only needed for non-EU workers.

According to figures from the Office for National Statistics, there is currently an estimated 2.31 million EU nationals working in the UK and these changes could affect many sectors reliant on attracting new talent and staff from overseas. Aldijana Hoad, director at immigration law firm OTB Legal acknowledges that with the country still in the grip of the Covid-19 crisis, Brexit is something far from our minds.

We understand that for some companies, the future is uncertain, and many are focusing to how to survive and operate in the future, so to have something else to think about right now is difficult, she said.

There were suggestions that the new immigration rules would be delayed because of Lockdown but the latest government guidance states they are still on track.

With this in mind, we want to stress how important it is for companies to apply for a Sponsor Licence now if they want to take on new EU nationals from overseas next year.

The rules are also being relaxed to allow bosses to employ overseas nationals with A-Level or equivalent standard skills from January.

Companies need to consider what the impact would be on their workforce and recruitment plans and subsequent delivery of goods and services

This compares to the degree level required previously when filling a vacancy and could see Sponsor Licence applications increase, as companies look to take on staff at different skill levels.

Aldijana said: With less than six months to prepare and an average two-month turnaround on the application process, its important to get started. Companies need to consider what the impact would be on their workforce and recruitment plans and subsequent delivery of goods and services, if there was a delay in getting a Sponsor Licence granted.

Over 15 per cent of Sponsor Licence Applications are refused due to issues such as companies not providing the required documents or not responding in a timely manner. If an application is refused, there is a cooling-off period of six months and a new application cant be made until after that date.

For companies currently employing EU nationals living in the UK, those individuals have until June 30, 2021 to apply to the Home Office for settled or pre-settled status under the EU Settlement Scheme. If they dont apply before then, they would lose their right to live and work here and would be illegally employed.

Its not just about attracting new staff but also protecting your existing workforce. It is vital for employers to complete right to work checks on anyone they take on as the consequence of employing someone illegally could be devastating, she said.

Penalties could be up to 20,000 per illegal worker, criminal sanctions, including up to five years imprisonment and/or an unlimited fine and companies could also face the loss of reputation as the Home Office publishes the names of businesses fined for employing illegal workers.

Our advice is to seek guidance to ensure everything is in order in good time, allowing you to protect the future of your business and your current workforce.

Excerpt from:

Freedom of movement and the importance of being Brexit-ready - SME Magazine

Nigel Farage’s attempts to spark another ‘Brexit’ in Italy – The New European

PUBLISHED: 12:43 25 July 2020

Steve Anglesey

Gianluigi Paragone, the former Five Star Movement senator who is heading up the new 'No Europe for Italy' party. Picture: Andrea Ronchini/NurPhoto via Getty Images

Andrea Ronchini/NurPhoto

After Nigel Farages role in Brexit, STEVE ANGLESEY looks at why he might be tempted to try to pull off something similar in Italy.

Email this article to a friend

To send a link to this page you must be logged in.

Become a Supporter

Almost four years after its creation The New European goes from strength to strength across print and online, offering a pro-European perspective on Brexit and reporting on the political response to the coronavirus outbreak, climate change and international politics. But we can only continue to grow with your support.

Mussolini can be quite funny, Nigel Farage told a Channel 4 reality show in 2014. I saw his granddaughter last week Pretty girl, pretty girl.

These are opinions Farage might want to keep on the QT now he appears to be acting as unofficial advisor to Italys version of the Brexit Party, which is due to launch this week. Since historians hold Mussolinis 20-year-long reign responsible for the deaths of one million of his countrymen, its just possible that not all Italians will chuckle along with Nigel at the thought of his memory.

Neither, youd imagine, would they be too impressed to learn that Hermann Kelly, who worked as a PR man for Farages EFDD grouping in the European parliament, used to refer to his boss as Il Duce (Thats just a bit of fun, isnt it, Nigel told Politico in 2018). Or to recall how in 2017, Farage was booed by Italian MEPs for comparing the EU to the mafia, later withdrawing his remark on the grounds of national sensitivities.

And you cannot see them looking too fondly on Farages speech in early March at the Daily Telegraphs Heroes of Brexit event, when he claimed Italys battle with Covid-19 presented a golden opportunity for Britain: This awful crisis and the way it is gripping parts of Italy makes a trade deal with the EU easier now than its ever, ever been. The collapsing Italian economy needs a deal with the UK desperately, he said.

None of this will matter much to Farage fanboy Gianluigi Paragone, the former Five Star Movement senator for who is heading up the new No Europe for Italy party names like Quitalia and Italexit having been deemed too Anglophone which is already polling around 7%. He calls Farage a true British patriot, hailing him for bringing the United Kingdom out of the European Union cage... the only one who sent away the technocrats from Brussels.

The former talk show host shares Farages awkward squad tendencies; public criticism of his partys fading commitment to Euroscepticism saw him kicked out of Five Star earlier this year. Paragone says the pair have discussed the present and future of a truly sovereign country which, even more so after Brexit, is able to give real answers to citizens in the midst of the post-Covid economic crisis.

Its hardly surprising to hear that Farage is interested in helping out. Along with the Denmark, Poland, the Netherlands and risibly Ireland, Italy is a country hes mentioned repeatedly as being prime for the next Brexit.

Until recently, the polls were firmly against him, with the Italian research institute Censis reporting late last year that only 25% believed leaving the EU was a good idea against 62% who thought it a bad idea. But the unions muddled response has been another silver lining from coronavirus for Farage; in April a Tecn poll put the numbers at an uncomfortable 51%-49% in favour of Remain.

Those polls are expected to move away from Leave after Italy became one of the key beneficiaries of the EU recovery fund that was finally agreed on Tuesday morning prime minister Giuseppe Conte says it will receive 28% of the 675 billion available in grants and loans but Farage has good reason to stay interested. Not only does it look like his lucrative private jet trips to the USA will become far more infrequent after Thursday, November 3, but Italy represents some kind of spiritual homeland for Brexit.

It was after discussions with Five Star co-founder Gianroberto Casaleggio in Milan in January 2015 that Farage resolved to make Facebook and data the key battlegrounds for pro-Leave campaigning, telling the political scientists Matthew Goodwin and Caitlin Milazzo: If I was starting UKIP today would I spend 20 years speaking to people in village halls or would I base it on the [Five Star co-founder Beppe] Grillo model? I know exactly what I would do.

Casaleggios methods attracted the eye of Arron Banks too, making the Milan meeting a fatal first step on the road to Leave just 17 months on. The Brexit Party, which toppled Theresa May and appears to have forced Britain into the kind of Brexit that in 2016 existed only in the wildest dreams of the wildest Leavers, was founded in Five Stars image.

Banks can now be found working for crotchety right-winger Winston Peters in his flagging New Zealand general election campaign against hugely popular incumbent PM Jacinda Ardern, telling website Newshub Nation this week that he is determined to deliver Winston on steroids a happy warrior.

Far cry, isnt it, from the days after Barack Obama delivered his pro-Remain Get to the back of the queue speech in March 2016? Back then, Banks organisation responded with a Back Off, Barack! petition and Farage warned him to butt out of the Brexit debate.

Honestly, the cheek of these foreigners trying to interfere in the democratic process of other countries...

Almost four years after its creation The New European goes from strength to strength across print and online, offering a pro-European perspective on Brexit and reporting on the political response to the coronavirus outbreak, climate change and international politics. But we can only rebalance the right wing extremes of much of the UK national press with your support. If you value what we are doing, you can help us by making a contribution to the cost of our journalism.

Read this article:

Nigel Farage's attempts to spark another 'Brexit' in Italy - The New European

Petition launched calling for European Union flag to be removed from outside Scottish Government buildings – HeraldScotland

A petition has been launched calling for the European Union flag to be taken down from outside Scottish Government buildings following Brexit.

The petition lodged on the Scottish Government site calls for the Scottish peoples view to be tested on the issue post-Brexit.

It comes after a move to stop flying the EU flag at the Scottish Parliament was shelved following a backlash from MSPs after ministers said that the flag should be flown in recognition of the contribution of EU national in Scotland.

READ MORE:EU negotiator warns post-Brexit trade deal unlikely

The Scotsman reports that Holyroods petition committee is now considering the issue after the petition was lodged by Philip Smith this month.

The petition reads: This petition is necessary to ensure the Scottish Government stops flying the flag of an organisation that the United Kingdom is no longer a member of, he states.

READ MORE:Iain Macwhirter: It's clear BoJo still doesnt get Scots (and its not the economy, stupid)

Although we have left the European Union, Scotland is still a member of the Commonwealth.

The petition should be allowed to test the Scottish peoples view on whether to have the Commonwealth flag flying in place of the European at Scottish Government buildings.

An example of where this has already taken place is Gibraltar which is now proudly flying the Commonwealth flag.

Responding to the petition, ministers told The Scotsman that the EU flag is flownto provide a concrete and visible expression of the value that we place on the contribution that EU nationals have made to our country.

The UK ceased to be a member of the European Union at the end of January, with talks continuing about the relationship after Brexit.The UKs chief negotiator, David Frost, said talks have not yet reached any agreement following intensified discussions between the two sides.

Excerpt from:

Petition launched calling for European Union flag to be removed from outside Scottish Government buildings - HeraldScotland

Brexit shock: How Northern Ireland could return to EU after UK departure – Daily Express

Northern Ireland was at the centre of the Brexit negotiations last year when former Taoiseach Leo Varadkar and Prime Minister Boris Johnson decided to settle the dispute over the Northern Ireland backstop. They agreed to put up a customs border in the Irish Sea in a move called the Northern Ireland Protocol, which would protect the Good Friday Agreement and prevent tensions returning to the Irish border. This means Northern Ireland will stay in the customs union and single market, but will no longer be able to contribute to the governance of either.

However, Stormont will be able to vote on whether to maintain this system every four years with the issue seemingly resolved, the Withdrawal Agreement came into effect in January.

Yet, as post-Brexit trade talks are on the cusp of collapse this week after Britain threatened to walk away, theres concern that there has not been enough preparation for the new system that will come into place in the Irish Sea.

Professor Colin Harvey, from Queens University Belfast, wrote for Irish broadcaster RTE back in 2019 that Brexit could lead Northern Ireland to rejoin the EU.

He claimed Brexit has had a destabilising impact on relationships across these islands.

Prof Harvey continued: The border on the island becomes an external border of the EU after Brexit, will all the symbolism that this carries combined with the severe practical implications.

He added the border is still of profound concern to the Irish Government and the EU.

He also claimed that the decision of the Democratic Unionist Party (DUP) to back Brexit divided Northern Ireland along unionist and nationalists.

Consequently, the DUP ended up on the opposite side of the table as the Remainers who made up the majority of the Northern Irish public by 56 percent.

READ MORE:Micheal Martins fury with UK for showing bad faith in Brexit demand

The Ireland expert added the likelihood of Irish reunification had been increased by Brexit.

He suggested that this was because the foundational objectives of the EU chime well with the values underpinning the peace process of the Good Friday Agreement.

Prof Harvey then said: The Good Friday Agreement contains a mechanism that would allow Northern Ireland to return automatically to the EU.

It is likely that interest in this will intensify.

He added that Northern Irelands status rests on the principle of consent which Mr Johnson attempted to address by allowing Stormont to vote on the matter every four years.

DON'T MISSFormer Taoiseach revived Project Fear with Northern Ireland warning[INSIGHT]EU hand laid bare: Ex-Irish PM admitted bloc is lobbying for no deal[EXPLAINED]How Northern Ireland turned on Boris Johnsons pilot project' in UK[REVEALED]

Prof Harvery continued: The EU has already provided clarification: the whole territory of a united Ireland would be part of the EU.

This opens a new dimension in the context of a society where a majority of people have voted to remain, and where many are profoundly worried about the impact of Brexit.

He pointed out how the arguments in favour of Irish unification will now include rejoining the EU, too.

Still, he conceded: The persuasiveness of this will depend on the type of Brexit that emerges, and much of this will have to be tested against what happens in practice.

He concluded: A no-deal Brexit or any form of hard Brexit will simply energise the unity discussion.

Prof Harveys piece in RTE was published just four days after Mr Johnson and Mr Varadkar claimed they saw a pathway to agreeing over Northern Ireland a pathway which led to the Northern Ireland Protocol.

However, Katy Hayward wrote in a blog post for LSE earlier this year that Stormonts consent on the Protocol did not have as much weight as previously thought.

She explained: In an effort to assure unionists in particular, the impression being given [by Westminster] is that, if they dont like the Protocol, they can invest efforts into getting rid of it via the democratic consent vote provided in Article 18.

The inclusion of Article 18 was itself an effort to assuage concerns in Northern Ireland (particularly those of unionists) that they would have no say over the Protocol.

She added: There are many aspects of it (e.g. articles on the protection of rights, safeguards and the Common Travel Area) that will apply regardless of how a majority of MLAs fall in a future consent vote.

To follow Prof Harveys logic, without consent in Northern Ireland for the post-Brexit arrangements, support for reunification and subsequently rejoining the EU could grow substantially.

See the rest here:

Brexit shock: How Northern Ireland could return to EU after UK departure - Daily Express

Uttlesford one of four negatively impacted by Brexit vote – Saffron Walden Reporter

PUBLISHED: 11:00 27 July 2020

Piers MeylerLocal Democracy Reporter

Four Essex districts are losers from the Brexit vote including Uttlesford, new research suggests. Picture: PA/ PA WIRE

Archant

Email this article to a friend

To send a link to this page you must be logged in.

Uttlesford, Southend, Rochford and Castle Point have all been performing worse financially after 2016 than models predicted Brexit had not happened, research from the University of Warwick has found.In Castle Point 72.7 percent of the electorate voted to leave, one of the highest leave votes in the country.Rochford voted 66.6 percent to leave.However, another four districts, namely Basildon, Brentwood, Chelmsford and Colchester have also performed worse than what otherwise would have been predicted without Brexit. All four voted to leave.Looking at the annual district-level data available up to 2018, the results suggest that among the 14 districts in Essex, eight recorded a 2018 gross value added that is smaller compared to their synthetic control while six report a higher value for 2018 compared to their synthetic control.Epping Forest is the biggest winner in Essex with an 18 percent difference in the gross value added compared to what would have been expected without Brexit.Thurrock, which voted 72.3 percent leave, was also categorised as a clear winner.In conclusion the researchers say: The research confirms existing work that has estimated that by 2018, Brexit has cost the UK economy at least two percent of real output.We find that these costs are far from evenly distributed across the UK. Within regions, districts whose regional economies depend heavily on manufacturing sector, appear to be particularly severely hit. Similarly, districts with relatively higher shares of residents with low educational attainment appear more exposed.Lastly, we also find that districts with higher support for Brexit in 2016 appear also more exposed to the Brexit-vote cost to date this highlights that quite likely, the cost of Brexit may exacerbate the already large regional economic disparities across regions in the UK.

This is particularly concerning as growing economic inequalities may further accelerate a trend that may result in the political disintegration of the United Kingdom.

If you value what this story gives you, please consider supporting the Saffron Walden Reporter. Click the link in the orange box below for details.

Read the original here:

Uttlesford one of four negatively impacted by Brexit vote - Saffron Walden Reporter

UK PM again insists fishing rights will not be traded in Brexit deal – Undercurrent News

UK prime minister Boris Johnson has said a Brexit trade deal can still be done by the end of the year, but warned he would not compromise on key issues like fishing rights, reports theScotsman.

He was speaking out after Brussels chief negotiator Michel Barnier said a trade deal between the UK and the EU was "unlikely" before the end of the year when the post-Brexit transition phase comes to an end.

The UKs chief negotiator David Frost also admitted after the latest round of talks that a deadline for a breakthrough by the end of July would be missed, adding that "we must face the possibility that one will not be reached".

But Johnson said he was hopeful a deal could be done before the end of 2020.

"[EU chiefs] are thinking 'my goodness thats a tall order'. But actually [no compromise on fisheries] is the right thing for the UK. In the early 1970s, we basically handed over control of our fisheries, we gave up our fisheries in the last throes of the Heath negotiations in a way that permanently disadvantaged UK fishers and Scottish fishers as well. Nows the time to change that and change that back."

Excerpt from:

UK PM again insists fishing rights will not be traded in Brexit deal - Undercurrent News

Despite Brexit, Donald Trump’s trade war with EU is putting thousands of Scottish jobs at risk Brian Wilson – The Scotsman

NewsOpinionColumnistsDonald Trumps administration is continuing to treat the UK as a member of the EU for the purpose of sanctions in the Airbus trade dispute and is about to extend its list of goods subject to prohibitive tariffs, writes Brian Wilson

Saturday, 25th July 2020, 7:30 am

Acting as faithful follower of American foreign policy has always carried risks as well as rewards.

The UK Government would do well to remember that historic truth before digging itself deeper into hostilities with China, in line with the current American way.

There was no shortage of reasons offered for pulling the plug on Huawei in the UK security initially topped the bill followed by Hong Kong and alleged human rights violations against the Uyghurs.

None of these is new and the general rule of international trade is that noses must be held if the show is to go on. Diplomacy rather than trade is the avenue for influencing errant states.

Ethical foreign policy is a noble concept but endlessly difficult to pursue consistently which is why it makes sense to separate it from trade, except in extreme circumstances.

The contention that these exist would have been more convincing if President Trump had not promptly informed the world that the UK ditched Huawei because he told them to, which is probably the truth of the matter.

One of the problems with pleading high-mindedness is that once started, there is no logical point to stop. If China is so awful, do we really want their students? Do we want them to control 25 per cent of the North Sea? Do we want them funding our infrastructure?

It is not as if China lacks options. They also have a fair grasp of their own history which does not necessarily predispose them to regard the UK as a font of virtue and righteousness, entitled to lecture them on how to conduct their affairs.

Presumably someone in Whitehall has noticed that Beijing is hoovering up soft power around the world with its astonishing Silk Road intiative which involves trillions of investment in scores of countries.

The Silk Road is not a geographically limiting term but flows from the concept of China as the worlds first global trader, regardless of oceans and borders. Via the Silk Road, it is seeking to regain that status from Africa to Latin America. Do they really need the UK that much?

A bellicose trade war with China in election year may be just what President Trump needs. It is less clear, as we walk away from the EU and reel from the Covid-19 aftermath, that it is what the UK needs.

And what of the United States on which we seem to be placing all available bets? It should not go unnoticed that, in the real world, our great ally across the water is currently waging a trade war against us not for us.

Though we are outside the EU, Washington continues to behave as if we are inside for the purpose of sanctions arising from the Airbus dispute. The World Trade Organisation authorised punitive US tariffs on random products in retaliation for illegal subsidies paid by Brussels.

Products targeted for prohibitive tariffs already include malt whisky, cashmere knitwear and shortbread. There is suspicion this selection reflects Trumps animus towards Scotland in light of the great fall-out which followed the great love-in. I know from personal experience remember the Banana Wars? that none of these things happen by accident.

Matters may be about to get much worse. By 12 August, the US will decide on an extension of the list which may include blended whisky and gin. Not everybody knows this, but 80 per cent of UK gin is now made in Scotland. If this happens, it is reckoned that 6,500 jobs are at risk.

It is surely time for the UK Government to call in whatever chips it holds in Washington to point out its not a good look to be attacked by your greatest ally at the same time as turning your back on past friends (the EU) and valuable partners (China).

Conversely, sorting this one out would be a decent advert not least in Scotland for taking back control. Failure to do so by 12 August will reinforce the alternative thought that with Trump as your best friend in the world, who needs enemies?

A message from the Editor:

Thank you for reading this article on our website. While I have your attention, I also have an important request to make of you.

With the coronavirus lockdown having a major impact on many of our advertisers - and consequently the revenue we receive - we are more reliant than ever on you taking out a digital subscription.

Subscribe to scotsman.com and enjoy unlimited access to Scottish news and information online and on our app. With a digital subscription, you can read more than 5 articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content. Visit http://www.scotsman.com/subscriptions now to sign up.

Our journalism costs money and we rely on advertising, print and digital revenues to help to support them. By supporting us, we are able to support you in providing trusted, fact-checked content for this website.

Go here to see the original:

Despite Brexit, Donald Trump's trade war with EU is putting thousands of Scottish jobs at risk Brian Wilson - The Scotsman

Hands Off British Steel! Brexit Party fury over Chinese takeover of vital UK industry – Express

Last year, the steel company plunged into insolvency after Government funding was scrapped and the Chinese company promised a "new chapter in British steelmaking".

Jingye, which is run by a former Communist Party official, paid around 70million for the acquisition and saved around 3,200 jobs.

But as tensions with Beijing grow, the Brexit Party are demanding UK infrastructure should be own by UK firms.

Nigel Farages party conducted a survey of 37,000 people asking, "Are you comfortable that the Chinese firm Jingye acquired British Steel in March 2020, given that it provides key steel supplies for UK infrastructure?"

Out of those who voted between July 12 and July 18, around 96 percent said they were uneasy with the Chinese taking over the company.

Posting the results on Twitter, the party said: Of 37,000 who took part in a survey of our supporters, 96 percent were uneasy with Jingyes takeover of British Steel.

46 percent said key UK infrastructure suppliers should be majority-owned by UK firms; 45 percent said they should be wholly owned by UK firms.

Announcing the news back in March, business secretary Alok Sharma said: Jingye has reached a significant milestone in securing a deal for the future of British Steel.

Work continues towards completing the sale, which will give certainty to British Steels dedicated and talented workforce in Scunthorpe, Skinningrove and on Teesside.

READ MORE:British Steel made with Russian coal leaves North East miners jobless

The Brexit Party anger comes after tensions between Britain and Beijing continue to rise.

Despite China having the second-largest economy in the world and its own space programme, it has emerged 71million of taxpayers money was given to the super-rich country in just one year, sparking calls for an inquiry.

The staggering figure was buried in the Department for International Developments annual report, which was put out this week as MPs go on their summer break.

The money is also being spent on training primary school teachers and combating illegal trade in wildlife, despite numerous exotic meat farms still running throughout the Communist nation.

DON'T MISSTurn off the tap! Boris ordered to stop taxpayer handouts to China[COMMENT]Andrew Pierce rages at UK 'outrageous' aid bill to China 'Infuriating'[INSIGHT]China's debt rockets as Beijing tries to recover from coronavirus[REVEAL]

According to reports, the money is also used to support human rights despite Beijings crackdown of Uyghur Muslims.

In light of the coronavirus pandemic, which was first reported in the Chinese city of Wuhan, Foreign Secretary Dominic Raab said 3billion would be cut from the aid budget next year.

Last week, the UK suspended its extradition treaty with Hong Kong in protest at the Chinese crackdown in the former British colony.

China responded with fury and warned they will make a forceful counter-attack, sparking fears of a World War 3 outbreak.

Mr Raab said the UK Government would not be re-activating the extradition treaty.

He said: We will not consider re-activating those arrangements, unless and until there are clear and robust safeguards, which are able to prevent extradition from the UK being misused under the new national security legislation.

The former British colony maintained its autonomy from Beijing since 1997 when the UK handed Hong Kong back to mainland China.

But in June, the Communist nation introduced a new security law viewed as an attempt to end Hong Kongs independence.

Prime Minister Boris Johnson condemned the move and promised to offer up to three million residents a route to UK citizenship.

Since the outbreak of COVID-19, China has become an international outcast following allegations of hacking, national security fears and human rights controversies.

Read the original here:

Hands Off British Steel! Brexit Party fury over Chinese takeover of vital UK industry - Express

Open Your Home Virtual Fitness Studio This Week With FitXR on Oculus Quest – VRFocus

Fitness focused virtual reality (VR) studio FitXR has brought its energetic app BoxVR to numerous headsets over the last three years, the last being Oculus Quest. Later this week the videogame will see a major update rollout for the standalone headset, adding new features and changing its name to FitXR.

The launch of FitXR aims to capture the energy of live fitness classes notes the studio, building on its experience with BoxVR by providing over four hours of boxing-inspired workouts. Designed to accommodate beginner, intermediate and advanced users, the workouts have been choreographed by professional fitness instructors so you get a full-body session.

A new feedback system will make it seem like you have your own personal trainer plus the launch will also see three DLC packs made available. Enhanced multiplayer features will allow six people to take part in on-demand classes (either live players or ghost data). Then later this year different workout styles will arrive.

With the launch of FitXR, we are ready to tackle the fitness industry head-on, said Sameer Baroova, Co-founder of FitXR in a statement. Traditional gym offerings can leave people unmotivated and at times intimidated our new studio offers a virtual fitness solution that is versatile and effective in helping people reach their fitness goals, but still remains fun at its core. Fun workouts are the ones we stick with, and this was the real driving force in creating FitXR.

The success of BoxVR has taught us that there is a massive public appetite for a fun and engaging way to work out that can be done from the comfort of your own home, Baroova continues. We know that people may not feel comfortable going back to public spaces and FitXR gives users the benefits of a group workout from home. The exciting thing about Virtual Reality fitness is that the possibilities really are endless that is why VR is the future of fitness. Were looking forward to the reaction from fans to the launch of FitXR, and cant wait to add new styles of workout to the studio.

FitXR will be released for Oculus Quest on 30th July 2020 as a free update for those that own BoxVR. FitXRs regular retail price will be $29.99 USD/22.99 GBP. For further updates, keep reading VRFocus.

View post:

Open Your Home Virtual Fitness Studio This Week With FitXR on Oculus Quest - VRFocus

Augmented and Virtual Reality Software and Service Industry Market Size, Development, Key Opportunity, Application & Forecast to 2025 -…

A detailed research on 'Augmented and Virtual Reality Software and Service Industry market' recently added by Market Study Report, LLC, puts together a concise analysis of the growth factors impacting the current business scenario across assorted regions. Significant information pertaining to the industrys size, share, application, and statistics are also summed in the report in order to present an ensemble prediction. In addition, this report undertakes an accurate competitive analysis illustrating the status of market majors in the projection timeline, while including their expansion strategies and portfolio.

The Augmented and Virtual Reality Software and Service Industry market report is an in-depth analysis of this business space. The major trends that defines the Augmented and Virtual Reality Software and Service Industry market over the analysis timeframe are stated in the report, along with additional pointers such as industry policies and regional industry layout. Also, the report elaborates on the impact of existing market trends on investors.

Request a sample Report of Augmented and Virtual Reality Software and Service Industry Market at:https://www.marketstudyreport.com/request-a-sample/2793185?utm_source=ALG&utm_medium=RV

COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.

Other information included in the Augmented and Virtual Reality Software and Service Industry market report is advantages and disadvantages of products offered by different industry players. The report enlists a summary of the competitive scenario as well as a granular assessment of downstream buyers and raw materials.

Revealing a gist of the competitive landscape of Augmented and Virtual Reality Software and Service Industry market:

Ask for Discount on Augmented and Virtual Reality Software and Service Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2793185?utm_source=ALG&utm_medium=RV

An outlook of the Augmented and Virtual Reality Software and Service Industry market regional scope:

Additional takeaways from the Augmented and Virtual Reality Software and Service Industry market report:

This report considers the below mentioned key questions:

Q.1. What are some of the most favorable, high-growth prospects for the global Augmented and Virtual Reality Software and Service Industry market?

Q.2. Which products segments will grow at a faster rate throughout the forecast period and why?

Q.3. Which geography will grow at a faster rate and why?

Q.4. What are the major factors impacting market prospects? What are the driving factors, restraints, and challenges in this Augmented and Virtual Reality Software and Service Industry market?

Q.5. What are the challenges and competitive threats to the market?

Q.6. What are the evolving trends in this Augmented and Virtual Reality Software and Service Industry market and reasons behind their emergence?

Q.7. What are some of the changing customer demands in the Augmented and Virtual Reality Software and Service Industry Industry market?

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-augmented-and-virtual-reality-software-and-service-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. COVID-19 Outbreak-Global Analytics Software Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-analytics-software-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

2. COVID-19 Outbreak-Global Laboratory Information System Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-laboratory-information-system-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Here is the original post:

Augmented and Virtual Reality Software and Service Industry Market Size, Development, Key Opportunity, Application & Forecast to 2025 -...

Study: Are strong leaders as effective in a virtual world? – KAMR – MyHighPlains.com

Study shows strong in-person leaders may not be as good of a fit for spearheading virtual teams.

by: Fox News

(FOX NEWS) Can leaders in the face-to-face world lead as well in online meetings?

A new study suggests what works well with leaders, in reality, may not work in virtual reality.

Brigham Young University researchers studying 220 student teams at two different Midwestern universities to learn if in-person leadership fits the new online virtual world of meetings and teams.

The study concluding virtual teams are more action-oriented, preferring leaders who monitor timelines, provide feedback, and coordinate teamwork.

Virtual team leaders also need to stand out as the leaders and Soft skills used for in-person settings may not translate as well to virtual situations.

New training for the virtual age of online meetings may be needed for traditional leaders.

The study published in the Journal of Business and Psychology.

More from MyHighPlains.com:

More:

Study: Are strong leaders as effective in a virtual world? - KAMR - MyHighPlains.com